Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a locally advanced or metastatic solid tumor with a KRAS G12V mutation confirmed by a lab test.
- You must have tried standard treatments (including targeted therapy) and your cancer got worse or you couldn't tolerate them.
- Your tumor must be measurable on scans (like CT or MRI).
- You must be able to swallow and take pills by mouth.
- You cannot have had a previous treatment that targets KRAS G12V or other RAS-related therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
This trial tests an experimental drug called LT-010391 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The drug is designed to target this mutation, and the study aims to see if it can help when standard treatments are no longer working.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.